Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since the discovery of induced pluripotent stem cells (iPSCs) by the transduction of four factors (OCT3/4, SOX2, c-MYC, and KLF4) in mouse embryonic fibroblasts. Initial studies on iPSCs led to direct-conversion techniques using transcription factors expressed mainly in target cells. However, reprogramming transcription factors with a virus risks integrating viral DNA and can be complicated by oncogenes. To address these problems, many researchers are developing reprogramming methods that use clinically applicable small molecules and growth factors. This review summarizes research trends in reprogramming cells using small molecules and growth factors, including their modes of action.

Hyeryeon Jeon, Kyojin Kang, Su A Park, Wan Doo Kim, Seung Sam Paik, Sang-Hun Lee, Jaemin Jeong, and Dongho Choi. Gut and Liver 2017;11:121-8. https://doi.org/10.5009/gnl16010

Soo Young Lee, Han Joon Kim, and Dongho Choi. IJSC 2015;8:36-47. https://doi.org/10.15283/ijsc.2015.8.1.36

Kim Y, et al. Ann Surg Treat Res. 2017 Feb;92(2):67-72. https://doi.org/10.4174/astr.2017.92.2.67